دورية أكاديمية
أعرض في EDS

Fibroblastic reticular cells orchestrate long-term graft survival following recipient treatment with CD40 ligand-targeted costimulatory blockade.

التفاصيل البيبلوغرافية
العنوان: Fibroblastic reticular cells orchestrate long-term graft survival following recipient treatment with CD40 ligand-targeted costimulatory blockade.
المؤلفون: Fairchild RL
المصدر: The Journal of clinical investigation [J Clin Invest] 2022 Dec 15; Vol. 132 (24). Date of Electronic Publication: 2022 Dec 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
أسماء مطبوعة: Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
Original Publication: New Haven [etc.] American Society for Clinical Investigation.
مواضيع طبية MeSH: CD40 Ligand* , Graft Survival*, Mice ; Animals ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; T-Lymphocytes ; Antibodies, Monoclonal/pharmacology ; CD40 Antigens ; Graft Rejection
مستخلص: Fibroblastic reticular cells (FRCs) maintain the architecture of secondary lymphoid organs, which optimize interactions between antigen-presenting dendritic cells and reactive naive T cells. In this issue of the JCI, Zhao, Jung, and colleagues investigated CD4+FoxP3+ regulatory T cell development and long-term heart allograft survival in recipients treated with peritransplant costimulatory blockade to inhibit CD40/CD40 ligand (CD40L) signaling. Treatment with an anti-CD40L monoclonal antibody (mAb) increased the lymph node (LN) population of Madcam1+ FRCs and altered their transcription profile to express immunoregulatory mediators. Administration of nanoparticles, containing the anti-CD40L mAb and a targeting antibody against high endothelial venules, delivered the treatment into LNs of allograft recipients. Direct LN delivery of the costimulatory blockade allowed decreased dosing and increased the efficacy in extending graft survival. The results provide insights into mechanisms by which FRCs can promote donor-reactive tolerance, and establish a strategy for administering costimulation-blocking reagents that circumvent systemic effects and improve allograft outcomes.
References: J Exp Med. 2010 Apr 12;207(4):689-97. (PMID: 20308362)
Nat Immunol. 2015 Jan;16(1):75-84. (PMID: 25347465)
Transplantation. 2004 Feb 15;77(3):460-2. (PMID: 14966427)
Sci Immunol. 2020 Sep 11;5(51):. (PMID: 32917792)
N Engl J Med. 2016 Jan 28;374(4):333-43. (PMID: 26816011)
J Immunol. 2021 Jan 15;206(2):257-263. (PMID: 33397739)
Curr Opin Organ Transplant. 2019 Aug;24(4):391-401. (PMID: 31157670)
Immunity. 2012 Aug 24;37(2):276-89. (PMID: 22884313)
Nat Immunol. 2020 Apr;21(4):369-380. (PMID: 32205888)
Transplantation. 1996 Jan 15;61(1):4-9. (PMID: 8560571)
J Clin Invest. 2020 Aug 3;130(8):4182-4194. (PMID: 32597832)
Nature. 2014 Oct 23;514(7523):498-502. (PMID: 25341788)
J Clin Invest. 2022 Jul 1;132(13):. (PMID: 35775481)
Immunity. 2018 May 15;48(5):1014-1028.e6. (PMID: 29752062)
Am J Transplant. 2020 Feb;20(2):463-473. (PMID: 31647605)
J Clin Invest. 2020 May 1;130(5):2602-2619. (PMID: 32017712)
Trends Immunol. 2021 Aug;42(8):723-734. (PMID: 34256989)
Am J Transplant. 2017 May;17(5):1182-1192. (PMID: 28097811)
Nat Immunol. 2007 Nov;8(11):1255-65. (PMID: 17893676)
PLoS Biol. 2016 Jul 14;14(7):e1002515. (PMID: 27415420)
Nat Med. 1999 Jun;5(6):686-93. (PMID: 10371508)
Nat Rev Nephrol. 2014 Jan;10(1):14-24. (PMID: 24100403)
Immunol Rev. 2021 Jul;302(1):32-46. (PMID: 34046914)
المشرفين على المادة: 147205-72-9 (CD40 Ligand)
0 (Antibodies, Monoclonal)
0 (CD40 Antigens)
تواريخ الأحداث: Date Created: 20221215 Date Completed: 20221216 Latest Revision: 20221223
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9753987
DOI: 10.1172/JCI165174
PMID: 36519546
قاعدة البيانات: MEDLINE
الوصف
تدمد:1558-8238
DOI:10.1172/JCI165174